In a key post-recall milestone, Philips says it has more than doubled its number of 510(k) clearances from the U.S. Food and Drug Administration (FDA) over the past two years.

Philips says it has completed actionable registrations across sleep therapy and ventilator devices and is closing the U.S. Patient Portal related to its recall as of Jan. 1, 2026.

Exor NV, the Agnelli family's investment arm, has acquired a 15% stake in Philips for $2.8 billion, making them the top ...